Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2021 - 11 - 30 save search
Gates Industrial to Participate in Credit Suisse's 9th Annual Global Industrials Conference
Published: 2021-11-30 (Crawled : 23:00) - prnewswire.com
GTES | $17.18 -0.52% 0.0% 1M
|
Producer Manufacturing
|
| O: 0.8%
H: 0.61%
C: -2.51%
trials trial conference
Dycom Industries, Inc. to Participate in the 3rd Annual Truist Securities Industrials and Services Virtual Summit
Published: 2021-11-30 (Crawled : 22:00) - globenewswire.com
DY | $134.71 -0.03% 0.0% 170K
|
Industrial Services
|
| O: 1.18%
H: 0.45%
C: -5.9%
trials trial
Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients
Published: 2021-11-30 (Crawled : 21:00) - globenewswire.com
LGVN | News P 0 d | $2.005 -4.07% -4.24% 990K
|
|
| O: -8.73%
H: 6.96%
C: -14.84%
phase 2 trial test lomecel-b
Global Industrial Valves and Actuators Market Report 2021: Future Growth Potential Driven by the Shift Toward Sustainable Energy and Technology Enabled New Business Models
Published: 2021-11-30 (Crawled : 20:00) - prnewswire.com
FLS | $45.63 -0.09% 0.0% 1M
|
Producer Manufacturing
|
| O: 0.36%
H: 1.24%
C: -3.62%
technology trial energy potential growth
Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ENSC | $0.5805 -7.83% -8.49% 90K
|
Health Technology
|
| O: 2.83%
H: 0.0%
C: 0.0%
trial opioid bioscience
Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
atopic dermatitis expansion dermatitis urticaria
Kintara Announces First International Site Activation in GCAR Phase 2/3 Clinical Trial for Glioblastoma
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
KTRA | $0.1059 2.02% 1.98% 1.7M
|
Distribution Services
|
| O: 0.0%
H: 1.04%
C: -2.78%
phase 2 phase 2/3 trial glioblastoma
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
risk trial positive cancer phase 3 breast cancer initiated her2- her2
Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
JAZZ | $109.3 2.05% 2.01% 560K
|
Health Technology
|
| O: -3.5%
H: 0.0%
C: 0.0%
trial lung cancer cancer phase 3 enroll
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
retina
CNH Industrial completes the acquisition of Raven Industries
Published: 2021-11-30 (Crawled : 13:30) - globenewswire.com
CNHI | News | $12.4 0.32% 1.13% 6.1M
|
Producer Manufacturing
|
| O: -2.07%
H: 0.0%
C: 0.0%
acquisition trial
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
Published: 2021-11-30 (Crawled : 13:30) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -4.99%
H: 0.0%
C: 0.0%
treatment renal trial therapeutics collaboration cell carcinoma
Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way
Published: 2021-11-30 (Crawled : 13:00) - ir.hoththerapeutics.com
HOTH | $1.23 0.0% 20K
|
Health Technology
|
| O: 0.06%
H: 4.32%
C: -1.8%
atopic dermatitis phase 1 dermatitis phase 1b trial therapeutics enroll phase 2b
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Published: 2021-11-30 (Crawled : 13:00) - biospace.com/
CYBN | News | $0.3699 -1.47% 1.05% 1.7M
|
n/a
|
| O: 3.4%
H: 0.66%
C: -3.29%
new drug fda phase 2 drug trial approval covid
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
Published: 2021-11-30 (Crawled : 13:00) - biospace.com/
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: -10.85%
H: 0.0%
C: 0.0%
disease risk bacterial infections phase 1 phase 1b bacteria iot therapeutics enroll infections phase 2b
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
Published: 2021-11-30 (Crawled : 12:30) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 39.31%
H: 0.0%
C: 0.0%
positive results cancer ovarian cancer trial mirvetuximab topline
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
Published: 2021-11-30 (Crawled : 12:00) - globenewswire.com
FWBI | $2.82 -2.76% -2.84% 38K
|
Manufacturing
|
| O: 42.63%
H: 0.0%
C: 0.0%
treatment biopharma test positive gastrointestinal trial covid infections
Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine
Published: 2021-11-30 (Crawled : 12:00) - biospace.com/
ATHX | $0.1018 -40.86% 95M
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: 0.0%
therapy respiratory trial syndros
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.